Director Williams buys 400 shares of CCFN at $60.00 on 2026-01-29; 0 of 3 prior same-ticker buys yielded positive 90d returns.
Director Brenda R H Williams purchased 400 shares at $60.00, increasing holdings by 22.2% to 2,200 shares. However, this purchase comes amid a consistent pattern of poorly-timed buys at this ticker: her 5 prior CCFN trades show a 0.00% win rate at the 90-day mark, with returns ranging from -63.1% to -67.4%. Her cross-ticker track record shows 0 of 6 prior buys succeeded within 30 days (average -65.8% return), and all 6 failed at 90 days (average -64.0%, 0% win rate). While 3 other insiders also bought CCFN in the past 14 days, suggesting possible coordinated action, the current price of $19.78 is -67% below the transaction price of $60.00, indicating the stock has declined sharply since purchase. The company's valuation metrics (P/E of 3.17 on $6.7M net income) warrant scrutiny, but the insider's pattern of adverse timing outcomes is the dominant signal.
Director Brenda R H Williams purchased 75 shares at blended $55.46 on Dec 11–12; position now 1,800 shares. Stock down 67% from her Oct 2025 buy.
Williams made 2 separate purchases totaling 75 shares for $4,159.25 at an average price of $55.46. However, the current price of $18.25 indicates the stock has declined significantly from her recent purchase prices—she is underwater on both the current transaction and on her prior same-ticker purchases at CCFN. Her prior buying history at this ticker shows a consistent pattern: the October 2025 buy delivered a 30-day return of -67.0%, and three earlier 2024 purchases each resulted in 90-day returns between -64.4% and -64.5%. Across her cross-ticker track record, her 4 prior buys averaged -65.2% over 30 days and -64.3% over 90 days, with a 0.00% 90-day win rate. The continued accumulation despite steep underwater positions on prior purchases at this ticker, combined with her poor historical timing across both this ticker and her broader portfolio, suggests little predictive value in the purchase as a positive signal for near-term recovery.
Director Brenda R H Williams bought 150 CCFN shares at $53.00 on 2025-10-29; prior trades at this ticker show 0 of 3 well-timed at 90d mark.
Director Brenda R H Williams purchased 150 shares of MUNCY COLUMBIA FINANCIAL Corp at $53.00, increasing her holdings by 9.5% to 1,725 shares total. However, her track record at this specific ticker presents a material concern: all 3 prior CCFN purchases generated significant losses within 90 days (ranging from -64.0% to -64.8%), with a 0.00% win rate at the 90-day mark. Her cross-ticker open-market history is similarly poor, with an average 90-day return of -64.3% across 3 prior buys and a 90-day win rate of 0.00%. The current stock price of $17.40 is substantially below the transaction price of $53.00, suggesting the earlier purchases have deteriorated significantly. While CCFN trades at an attractive P/E of 3.02, the consistency of poor outcomes on this insider's prior CCFN purchases raises questions about trade timing or judgment.
Director Brenda R H Williams bought 125 shares of CCFN at $39.85 on 2024-12-10, raising holdings to 1,575 shares
Director Williams purchased 125 shares at $39.85, increasing her holdings by 8.6% to 1,575 shares post-transaction. This represents her second discretionary buy at CCFN within eight days (prior buy on 2024-12-02), demonstrating continued accumulation at the company. The current market price of $13.67 sits at the 52-week high with a 30-day gain of 16.3% and 90-day gain of 20.6%, indicating strong recent price appreciation. The company trades at a notably compressed P/E of 3.87 with a market cap of $48,877,454.09, suggesting a small-cap position with limited valuation multiples.
Director Brenda R H Williams purchases 55 shares at blended $39.40; current price $12.33
Director Brenda R H Williams executed 2 separate purchases totaling 55 shares for $2,167.19 at a blended average price of $39.40 on 2024-12-02. Her post-transaction holdings reached 1,450 shares, an increase of 3.9% from the prior 1,395 shares. The current stock price of $12.33 is notably below the transaction prices ($39.40 blended, with individual trades at $39.45 and $39.35), indicating a significant decline since the purchase date. The company shows a low P/E of 3.49 and positive fundamentals with net income of $5,056,000.00, though the recent price deterioration has placed the stock -3.9% from its 52-week high of $12.83.
